
Acorda Therapeutics ACOR
Acorda Therapeutics Book Value | ACOR
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 109 M | 396 M | 455 M | 238 M | 311 M | 612 M | 520 M | 664 M | 598 M | 525 M | 440 M | 386 M | 205 M | 342 M | 319 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 664 M | 109 M | 408 M |
Quarterly Book Value Acorda Therapeutics
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81.6 M | 366 M | 365 M | 375 M | 396 M | 393 M | 406 M | 424 M | 455 M | 466 M | 491 M | 584 M | 633 M | 710 M | 728 M | 754 M | 800 M | 880 M | 1.2 B | 1.23 B | 1.3 B | 1.31 B | 1.25 B | 1.19 B | 1.2 B | 1.35 B | 1.33 B | 1.32 B | 1.34 B | 1.32 B | 1.35 B | 1.21 B | 1.11 B | 1.1 B | 1.1 B | 1.1 B | 1.07 B | 973 M | 943 M | 612 M | 607 M | 587 M | 576 M | 565 M | 565 M | 410 M | 403 M | 386 M | 379 M | 351 M | 336 M | 336 M | 331 M | 296 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.35 B | 81.6 M | 766 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Repare Therapeutics
RPTX
|
151 M | - | - | $ 112 M | ||
|
Sesen Bio
SESN
|
-27.9 M | - | 7.29 % | $ 127 M | ||
|
Windtree Therapeutics
WINT
|
13.2 M | - | - | $ 26.8 M | ||
|
Trean Insurance Group
TIG
|
315 M | - | - | $ 316 M | ||
|
SQZ Biotechnologies Company
SQZ
|
57.1 M | - | 57.95 % | $ 12.8 M | ||
|
MEI Pharma
MEIP
|
41.6 M | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
6.69 M | - | - | $ 13 M | ||
|
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
-10.7 M | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
57 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
125 M | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
86.2 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-38.9 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
648 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
190 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
212 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
63.9 M | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
3.24 B | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
7.16 M | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
1.83 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
18.6 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
21.5 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
154 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
27.3 M | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
98.7 M | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
4.16 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
80 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
928 M | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-473 M | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
38.9 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
205 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
8.15 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
46.8 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
156 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
15.1 M | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
163 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
-4.08 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
-914 K | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
-8.14 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
-45.3 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
6.12 M | - | 31.87 % | $ 1.61 M |